

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

InVivoMab anti-mouse CD28

RRID:AB_1107624

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0015-1, RRID:AB_1107624)

Antibody Information

URL: http://antibodyregistry.org/AB_1107624

Proper Citation: (Bio X Cell Cat# BE0015-1, RRID:AB_1107624)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: Agonistic Antibodies, in vivo Neutralization & Blocking

Antibody Name: InVivoMab anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: clone 37.51

Antibody ID: AB_1107624

Vendor: Bio X Cell

Catalog Number: BE0015-1

Alternative Catalog Numbers: BE0015-1-50MG, BE0015-1-1MG, BE0015-1-100MG, BE0015-1-5MG, BE0015-1-25MG

Record Creation Time: 20260114T193009+0000

Record Last Update: 20260623T051048+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse CD28.

No alerts have been found for InVivoMab anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 115 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Meitei HT, et al. (2026) CCL20-CCR6 signaling alters the metabolic reprogramming to promote the pathogenic Th17 cell differentiation. *iScience*, 29(1), 114385.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

Wang Y, et al. (2025) Cognate interaction-dependent pathogenicity of meningeal B cells drives neuroinflammation relapse. *Immunity*, 58(9), 2256.

Shimba A, et al. (2025) Stress-induced glucocorticoids enhance acute inflammation by promoting the differentiation of Th17 cells. *Cell reports*, 44(8), 116093.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8⁺ T cells. *Immunity*, 58(10), 2472.

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Zhang G, et al. (2025) GD2TIF cells as a platform for single-dose and long-term delivery of biologics. *Nature communications*, 16(1), 8088.

Zhang Y, et al. (2025) Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. *Cancer cell*, 43(9), 1677.

Jiang Y, et al. (2025) Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. *Cell*, 188(9), 2354.

Ma Y, et al. (2025) TMEM41B is an endoplasmic reticulum Ca²⁺ release channel maintaining naive T cell quiescence and responsiveness. *Cell discovery*, 11(1), 18.

Rebeaud J, et al. (2025) Gut-derived metabolites drive Th17 cell pathogenicity in multiple sclerosis. *Cell reports*, 44(10), 116326.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Yuan Y, et al. (2025) USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 122(38), e2510576122.

Look T, et al. (2025) CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. *Cell reports. Medicine*, 6(2), 101931.

Wang C, et al. (2025) Gut microbe-derived metabolites drive psoriatic inflammation via modulation of skin Th17 cells. *Immunity*, 58(9), 2241.

Ng II, et al. (2025) Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity via the cGAS/STING pathway. *Cell reports*, 44(6), 115733.

Qian Y, et al. (2025) Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic "selection trap" and thymic atrophy. *Cell reports*, 45(1), 116762.

Xiao J, et al. (2025) Uridine depletion impairs CD8⁺ T cell antitumor activity through N-glycosylation. *Cell metabolism*.

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. *Immunity*, 58(3), 745.

Guo X, et al. (2025) Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer. *Cancer cell*, 43(2), 248.